Gen XY Updates from GlobeNewswire

Expanse Studios Secures Swedish B2B Gaming License
2025-12-02T18:05:38Z
VALLETTA, Malta and LAS VEGAS, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Expanse Studios, a B2B iGaming content provider and subsidiary of Golden Matrix Group Inc. (NASDAQ: GMGI), has been granted...

AMPS Achieves HITRUST e1 Certification, Solidifying Commitment to Data Security in Healthcare
2025-12-02T17:17:59Z
PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- AMPS, a healthcare technology solutions company serving self-insured employer groups, payors, healthcare brokers and consultants, and third-party administrators, announced today that its enterprise...

Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases
2025-12-02T17:15:00Z
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Chief Executive Officer Greg...

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
2025-12-02T17:13:55Z
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III clinical trial...

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
2025-12-02T17:13:55Z
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III clinical trial...

IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025
2025-12-02T17:00:00Z
Attachment

GUERBET : Adjustment of 2025 financial targets.
2025-12-02T16:45:00Z
Adjustment of 2025 financial targets

NUAIR's Military-Tested Surveillance Network Advances White House Vision for American Airspace Sovereignty
2025-12-02T16:30:00Z
FAA-approved third-party infrastructure proves ready for national deployment as Task Force priorities take shape

Finland Unveils New B2B Operating Model: Mandatory Supplier Licensing and Veikkaus Split Confirmed for 2027
2025-12-02T16:17:10Z
Helsinki-based industry analyst Bonusetu breaks down the new dual-license structure and the legal separation of the state monopoly, citing crucial data for operators planning market entry.

Health-ISAC® Announces results of 2026 Board of Directors Election
2025-12-02T15:30:00Z
ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center (Health-ISAC), the non-profit world-class, industry-led sharing organization that provides the global health sector with a trusted...

LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
2025-12-02T15:28:01Z
EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION

LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
2025-12-02T15:28:01Z
EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION

Sun Country Airlines to Establish New Base in Cincinnati/Northern Kentucky (CVG)
2025-12-02T15:00:00Z
MINNEAPOLIS, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sun Country Airlines (NASDAQ: SNCY) will open a new operational base at Cincinnati/Northern Kentucky International Airport, Hebron, KY (CVG) in early 2026. This...

Precision Neuroscience Recognized for Innovation and Responsible Technology with Two Industry Awards
2025-12-02T14:34:31Z
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision™) a leader in brain–computer interface (BCI) technology, has been named to Inc. Magazine’s 2025 Best in Business list...

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
2025-12-02T14:29:00Z
TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on...

INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2025-12-02T14:25:00Z
SARASOTA, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced that it has...

Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
2025-12-02T14:17:26Z
PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that its stockholders approved, among other things, the proposed business...

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
2025-12-02T14:15:00Z
Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel’s advancement across large unmet-need global markets

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
2025-12-02T14:15:00Z
MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that...

BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from the Italian Ministry of Health Approval to conduct its clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
2025-12-02T14:00:00Z
MILAN, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid...

ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors
2025-12-02T14:00:00Z
– Dr. Tagliaferri is a proven executive recognized for advancing innovative therapies across immunology, oncology and other serious diseases –

Aeroflow Health Celebrates Giving Tuesday Through Donations to Western North Carolina Organizations
2025-12-02T14:00:00Z
Aeroflow donates several thousand dollars across seven local organizations based in its home state

Reema Health Tackles Medicaid Challenges with $19M Series B from LRVHealth and Optum Ventures
2025-12-02T14:00:00Z
Engagement Model Blending Humans and Technology Drives 3X ROI to Medicaid MCOs

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
2025-12-02T14:00:00Z
- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer -

Citizen Health Joins Forces with UCB to Accelerate Drug Development across Epilepsy and Rare Diseases
2025-12-02T14:00:00Z
The multi-year partnership launches with focus on epilepsy, rare disease and AI

Orbus Therapeutics Announces Publication of Phase 3 STELLAR Clinical Study Results Showing Clinically Meaningful Improvements in Rare Brain Tumor in Journal of Clinical Oncology (JCO)
2025-12-02T14:00:00Z
– Eflornithine and lomustine combination doubled progression free survival (PFS) and improved overall survival (OS) in patients with recurrent Grade 3 astrocytoma –

Season Health and Albertsons Companies Launch Community Supports Service in California
2025-12-02T14:00:00Z
Eligible Medi-Cal members in Contra Costa County can now receive medically tailored grocery bundles from Safeway stores

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection
2025-12-02T14:00:00Z
Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations,...

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
2025-12-02T13:50:00Z
Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trials

Cannabix Technologies Strengthens Presence in Maritime Market with Repeat BreathLogix Alcohol Screening Device Order
2025-12-02T13:45:00Z
VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is...

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
2025-12-02T13:45:00Z
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
2025-12-02T13:45:00Z
WOBURN, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today...

PolarityBio Completes Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers
2025-12-02T13:31:00Z
SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- PolarityBio©, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative skin multicellular therapy,...

rYojbaba Announces the Launch of AI-Powered Worker Risk Intelligence Platform
2025-12-02T13:30:00Z
FUKUOKA, Japan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) ("rYojbaba" or the "Company"), a Japanese labor consulting and health services company, announced the launch of an AI-powered...

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
2025-12-02T13:30:00Z
Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway

CasinoTrac™ Signs S&K Gaming, LLC of Montana
2025-12-02T13:30:00Z
MINNETONKA, MINN., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Table Trac, Inc. (OTCQX: TBTC) today announced it will deliver its CasinoTrac casino management system (“CMS”), to S&K Gaming, LLC, a wholly...

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
2025-12-02T13:30:00Z
WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has received the...

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
2025-12-02T13:30:00Z
AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially...

CYIOS Corp. Appoints John O’Shea as Chief Executive Officer to Lead Next Phase of Growth and Innovation
2025-12-02T13:30:00Z
MELBOURNE, Australia and PALM BEACH, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CYIOS Corp. (OTC: CYIO), a diversified holding company focused on acquiring, building, and scaling high-growth businesses in the...

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
2025-12-02T13:30:00Z
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically...

Gelteq to Present at Investor Summit Virtual on December 9, 2025
2025-12-02T13:30:00Z
MELBOURNE, Australia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (Nasdaq: GELS) (“Gelteq”) today announced that Nathan Givoni, its Chief Executive Officer, will present at the Q4 Investor Summit Virtual on...

CORRECTION: Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery
2025-12-02T13:27:38Z
Pluristyx to lead a new public-private consortium with 9 other industry leaders to establish global standards for non-animal drug testing models

SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI
2025-12-02T13:27:00Z
FDA lowers surveillance requirement to 50 patients from 300 patients in original HDE approval based on assessment of first 21 SAVE Surveillance Registry patients

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
2025-12-02T13:05:00Z
RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
2025-12-02T13:05:00Z
COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients,...

BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025
2025-12-02T13:05:00Z
MENLO PARK, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to...

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
2025-12-02T13:05:00Z
SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of precision oncology diagnostics with expanding operations across Southeast Asia, today...

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
2025-12-02T13:02:00Z
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
2025-12-02T13:01:00Z
DNA-based Colorectal Cancer Screening as a Home Test

Amneal to Participate in Upcoming Investor Conferences
2025-12-02T13:00:00Z
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate...